{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:22:45Z","timestamp":1788830565197,"version":"build-2803163510"},"reference-count":22,"publisher":"Baskent University","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.6002\/ect.2018.0236","type":"journal-issue","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T10:23:46Z","timestamp":1537871026000},"source":"Crossref","is-referenced-by-count":1,"title":[],"prefix":"10.6002","volume":"16","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","author":"Shitara","year":"2018","unstructured":"Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. (2018). Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 392(10142):123-33","journal-title":"Lancet"},{"key":"ref1","unstructured":"U.S. Food and Drug Administration: FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication [updated May 30, 2017. Available from: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm560040.htm."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310839","article-title":"Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma","author":"Thompson","year":"2017","unstructured":"Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, et al. (2017). Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 66:794-801","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0046","article-title":"Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma","author":"Derks","year":"2015","unstructured":"Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, et al. (2015). Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 3:1123-9","journal-title":"Cancer Immunol Res"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kelly RJ, Zaidi AH, Smith MA, Omstead AN, Kosovec JE, Matsui D, et al. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. Annals of surgery. 2017.","DOI":"10.1097\/SLA.0000000000002410"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8777","article-title":"Emerging therapeutic targets in esophageal adenocarcinoma","author":"Gaur","year":"2016","unstructured":"Gaur P, Hunt CR, Pandita TK. (2016). Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget. 7:48644-55","journal-title":"Oncotarget"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2591","article-title":"Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity","author":"Dulak","year":"2013","unstructured":"Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, et al. (2013). Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nature genetics. 45:478-86","journal-title":"Nature genetics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","author":"Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine. 373:123-35","journal-title":"The New England journal of medicine"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","author":"Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 373:23-34","journal-title":"The New England journal of medicine"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx212","article-title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study","author":"Cabel","year":"2017","unstructured":"Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, et al. (2017). Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol. 28:1996-2001","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0613","article-title":"Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma","author":"Xi","year":"2016","unstructured":"Xi L, Pham TH, Payabyab EC, Sherry RM, Rosenberg SA, Raffeld M. (2016). Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 22:5480-6","journal-title":"Clinical cancer research"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Raja R, Kuziora M, Brohawn P, Higgs BW, Gupta A, Dennis PA, et al. Early reduction in ctDNA predicts survival in lung and bladder cancer patients treated with durvalumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018.","DOI":"10.1158\/1078-0432.CCR-18-0386"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy","author":"Khagi","year":"2017","unstructured":"Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, et al. (2017). Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 23:5729-36","journal-title":"Clinical cancer research"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.05.080","article-title":"A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia","author":"Peters","year":"2010","unstructured":"Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, et al. (2010). A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 139:1995-2004 e15","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015074","article-title":"Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome","author":"Kim","year":"2010","unstructured":"Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, et al. (2010). Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PloS one. 5:e15074","journal-title":"PloS one"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.234179","article-title":"Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma","author":"Goh","year":"2011","unstructured":"Goh XY, Rees JR, Paterson AL, Chin SF, Marioni JC, Save V, et al. (2011). Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut. 60:1317-26","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.10.031","article-title":"Gene expression profiles in esophageal adenocarcinoma predict survival after resection","author":"Pennathur","year":"2013","unstructured":"Pennathur A, Xi L, Litle VR, Gooding WE, Krasinskas A, Landreneau RJ, et al. (2013). Gene expression profiles in esophageal adenocarcinoma predict survival after resection. J Thorac Cardiovasc Surg. 145:505-12; discussion 12-3","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2011.n.007","article-title":"Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer","author":"Rao","year":"2011","unstructured":"Rao S, Welsh L, Cunningham D, te-Poele RH, Benson M, Norman A, et al. (2011). Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer. Clin Colorectal Cancer. 10:48-56","journal-title":"Clin Colorectal Cancer"},{"key":"ref18","unstructured":"Motoori M, Takemasa I, Yamasaki M, Komori T, Takeno A, Miyata H, et al. (2010). Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. International journal of oncology. 37:1113-20"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181bce7e1","article-title":"Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer","author":"Maher","year":"2009","unstructured":"Maher SG, Gillham CM, Duggan SP, Smyth PC, Miller N, Muldoon C, et al. (2009). Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Annals of surgery. 250:729-37","journal-title":"Annals of surgery"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0048","article-title":"Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer","author":"Tamoto","year":"2004","unstructured":"Tamoto E, Tada M, Murakawa K, Takada M, Shindo G, Teramoto K, et al. (2004). Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 10:3629-38","journal-title":"Clinical cancer research"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2015.12.011","article-title":"A germline predictive signature of response to platinum chemotherapy in esophageal cancer","author":"Rumiato","year":"2016","unstructured":"Rumiato E, Boldrin E, Malacrida S, Battaglia G, Bocus P, Castoro C, et al. (2016). A germline predictive signature of response to platinum chemotherapy in esophageal cancer. Transl Res. 171:29-37 e1","journal-title":"Transl Res"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T16:47:18Z","timestamp":1571935638000},"score":1,"resource":{"primary":{"URL":"http:\/\/ectrx.org\/forms\/ectrxcontentshow.php?doi_id=10.6002\/ect.2018.0236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2018.0236","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}